Cite
HARVARD Citation
Kristeleit, R. et al. (n.d.). 386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab. International journal of gynecological cancer. pp. A40-A41. [Online].